



## Vaccine Development for Parasitic Disease

Guest Editors:

### Dr. Qingli Niu

Lanzhou Veterinary Research  
Institute, Chinese Academic of  
Agricultural Sciences, Lanzhou,  
China

### Surekha Shridhar

Center for Vaccine Development  
and Global Health, University of  
Maryland, 685 W. Baltimore  
Street, Baltimore, MD 20742, USA

Deadline for manuscript  
submissions:

**closed (30 April 2023)**

### Message from the Guest Editors

Dear Colleagues,

I am pleased to invite you to submit contributions to a Special Issue focused on human and veterinary vaccine research against well-known and emerging parasites that challenge human or animal health. We welcome articles on the development and evaluation of vaccines against parasitic infections. The scope of this Special Issue covers vaccine engineering, design, formulation, adjuvants, delivery and testing, as well as novel approaches to the discovery and characterization of antigens or small molecules that may be the foundation for novel therapeutics, and their associated immunological evaluations. The full experimental details must be provided so that the results can be reproduced, and any computed data or files regarding the full details of the experimental procedure can be deposited as Supplementary Materials.

I look forward to receiving your contributions.

Dr. Qingli Niu

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:**— free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** **JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)**

## Contact Us

---

*Vaccines*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)